NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

NCT02393898

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Ovarian Cancer

Interventions: Bevacizumab, Carboplatin, Paclitaxel

Countries: Belgium

The purpose of this study is to evaluate the safety and efficacy in the frontline treatment of ovarian cancer in participants 70 years of age and older in routine clinical practice in Belgium. Bevacizumab will be used in combination with carboplatin/paclitaxel followed by bevacizumab as maintenance in accordance with the Summary of Product Characteristics (SmPC).

Eligibility overview

Sex: FEMALE

Age: 70 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Aged 70 years and older
* No treatment with any other investigational agent within 28 days or 2 half-lives (whichever is longer) prior to enrollment

Exclusion Criteria:

* Contraindications, warnings, and precautions for bevacizumab

Locations (26)

Aalst, Belgium
Assebroek, Belgium
Bonheiden, Belgium
Brasschaat, Belgium
Bruges, Belgium
Brussels, Belgium
Brussels, Belgium
Charleroi, Belgium
Edegem, Belgium
Genk, Belgium
Ghent, Belgium
Ghent, Belgium
Ghent, Belgium
Haine-Saint-Paul, Belgium
Hasselt, Belgium
Kortrijk, Belgium
Leuven, Belgium
Liège, Belgium
Liège, Belgium
Liège, Belgium
Namur, Belgium
Ostend, Belgium
Sint-Niklaas, Belgium
Turnhout, Belgium
Verviers, Belgium
Wilrijk, Belgium